Healthcare [ 12/13 ] | Medical Devices [ 109/164 ]
NASDAQ | Common Stock
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
It operates in two segments, Codman Specialty Surgical and Tissue Technologies.
The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices.
In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection.
Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products.
The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally.
Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 24 | 0.55 Decreased by -25.68% | 0.55 |
| Feb 28, 24 | 0.89 Decreased by -5.32% | 0.90 Decreased by -1.11% |
| Oct 25, 23 | 0.76 Decreased by -11.63% | 0.78 Decreased by -2.56% |
| Jul 26, 23 | 0.71 Decreased by -12.35% | 0.57 Increased by +24.56% |
| Apr 26, 23 | 0.74 Increased by 0.00% | 0.74 |
| Feb 22, 23 | 0.94 Increased by +11.90% | 0.90 Increased by +4.44% |
| Oct 26, 22 | 0.86 Increased by 0.00% | 0.72 Increased by +19.44% |
| Jul 27, 22 | 0.81 Increased by +2.53% | 0.80 Increased by +1.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 368.87 M Decreased by -3.14% | -3.28 M Decreased by -113.54% | Decreased by -0.89% Decreased by -113.98% |
| Dec 31, 23 | 397.04 M Decreased by -0.25% | 19.83 M Decreased by -62.54% | Increased by +5.00% Decreased by -62.45% |
| Sep 30, 23 | 382.42 M Decreased by -0.72% | 19.50 M Decreased by -60.94% | Increased by +5.10% Decreased by -60.66% |
| Jun 30, 23 | 381.27 M Decreased by -4.16% | 4.18 M Decreased by -90.66% | Increased by +1.10% Decreased by -90.25% |
| Mar 31, 23 | 380.85 M Increased by +1.12% | 24.23 M Decreased by -26.37% | Increased by +6.36% Decreased by -27.18% |
| Dec 31, 22 | 398.02 M Decreased by -1.85% | 52.95 M Increased by +16.66% | Increased by +13.30% Increased by +18.86% |
| Sep 30, 22 | 385.19 M Decreased by -0.43% | 49.91 M Increased by +15.47% | Increased by +12.96% Increased by +15.97% |
| Jun 30, 22 | 397.81 M Increased by +2.01% | 44.79 M Increased by +27.72% | Increased by +11.26% Increased by +25.21% |